SELLAS Life Sciences Gr Q4 EPS $(0.25) Misses $(0.21) Estimate
Portfolio Pulse from Benzinga Newsdesk
SELLAS Life Sciences Gr (NASDAQ:SLS) reported a Q4 EPS loss of $(0.25), missing the consensus estimate of $(0.21) by 19.05%. This represents a 41.86% improvement over the $(0.43) loss per share from the same period last year.
March 29, 2024 | 3:35 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
SELLAS Life Sciences Gr reported a Q4 EPS loss of $(0.25), missing the consensus estimate of $(0.21) by 19.05%, yet showing a 41.86% improvement over last year's $(0.43) loss per share.
The miss in earnings per share (EPS) expectations could lead to a negative short-term reaction in SELLAS Life Sciences Gr's stock price. However, the improvement over last year's loss indicates some level of operational improvement, which might mitigate the negative impact to some extent.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100